Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

A recombinant vaccine based on domain II of Plasmodium vivax Apical Membrane Antigen 1 induces high antibody titres in mice

Full text
Author(s):
Show less -
Gentil, Fernanda [1] ; Bargieri, Daniel Y. [2] ; Leite, Juliana A. [3] ; Francoso, Katia S. [1] ; Patricio, Mariana B. M. [1] ; Espindola, Noeli M. [1] ; Vaz, Adelaide J. [1] ; Palatnik-de-Sousa, Clarisa B. [4] ; Rodrigues, Mauricio M. [2] ; Costa, Fabio T. M. [3] ; Soares, Irene S. [1]
Total Authors: 11
Affiliation:
[1] Univ Sao Paulo, Fac Ciencias Farmaceut, Dept Anal Clin & Toxicol, BR-05508900 Sao Paulo - Brazil
[2] Univ Fed Sao Paulo, Escola Paulista Med, CINTERGEN, BR-04044010 Sao Paulo - Brazil
[3] Univ Estadual Campinas, Dept Genet Evolucao & Bioagentes, Inst Biol, BR-13083862 Campinas, SP - Brazil
[4] Univ Fed Rio de Janeiro, Inst Microbiol Prof Paulo de Goes, BR-21941902 Rio De Janeiro - Brazil
Total Affiliations: 4
Document type: Journal article
Source: Vaccine; v. 28, n. 38, p. 6183-6190, AUG 31 2010.
Web of Science Citations: 26
Abstract

The Apical Membrane Antigen 1 (AMA-1) is considered a promising candidate for development of a malaria vaccine against asexual stages of Plasmodium. We recently identified domain II (DII) of Plasmodium vivax AMA-1 (PvAMA-1) as a highly immunogenic region recognised by IgG antibodies present in many individuals during patent infection with P. vivax. The present study was designed to evaluate the immunogenic properties of a bacterial recombinant protein containing PvAMA-1 DII. To accomplish this, the recombinant protein was administered to mice in the presence of each of the following six adjuvants: Complete/Incomplete Freund's Adjuvant (CFA/IFA), aluminium hydroxide (Alum), Quil A, QS21 saponin, CpG-ODN 1826 and TiterMax. We found that recombinant DII was highly immunogenic in BALB/c mice when administered in the presence of any of the tested adjuvants. Importantly, we show that DII-specific antibodies recognised the native AMA-1 protein expressed on the surface of P. vivax merozoites isolated from the blood of infected patients. These results demonstrate that a recombinant protein containing PvAMA-1 DII is immunogenic when administered in different adjuvant formulations, and indicate that this region of the AMA-1 protein should continue to be evaluated as part of a subunit vaccine against vivax malaria. (C) 2010 Elsevier Ltd. All rights reserved. (AU)